Table 2.
Overall transmission-blocking efficacy of serum derived from immunization with PbPfs25DR3 against field isolates of P. falciparum.
| PbPfs25DR3 Alhydrogel – 2 boost | PbPfs25DR3 Matrix M – 2 boost | ChAd63-Pfs25/PbPfs25DR3 Matrix M | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 in 5 | 1 in 10 | 1 in 100 | 1 in 5 | 1 in 10 | 1 in 100 | 1 in 5 | 1 in 10 | 1 in 100 | |
| Expt. A: | |||||||||
| Inhibition in intensity (%) | 77.3%*** | 47.8%** | 90.3%*** | 89.1%*** | 87.7%*** | 87.3%*** | 98.3%*** | 94.5%*** | 54.8%** |
| Inhibition in prevalence (%) | 9.5% | 0% | 38.1%*** | 19.1% | 26.2% | 42.0%* | 59.5%*** | 40.5%** | 4.7% |
| Expt. B: | |||||||||
| Inhibition in intensity (%) | 32.5%** | 45.6%*** | 27.0%* | 96.8%*** | 87.3%*** | 64.7%*** | 97.3%*** | 96.1%*** | 46.6%*** |
| Inhibition in prevalence (%) | 0% | 2.0% | −1.9% | 22.0% * | 13.7% | 4.7% | 46.0%*** | 26.1%** | 5.9% |
| Expt. C: | |||||||||
| Inhibition in intensity (%) | 89.0%*** | 59.4%** | 71.7%* | 83.1%*** | 68.5%* | 62.3%* | 91.5%*** | 90.8%*** | 29.7% |
| Inhibition in prevalence (%) | 89.1%*** | 50%** | 52.1%* | 70.8%** | 41.9% | 47.6%* | 87.5%*** | 83.3%*** | 7.7% |
| Overall inhibition: | |||||||||
| Inhibition in intensity (%) | 62.5%** | 46.9%* | 65.2%*** | 90.7%*** | 85.6%*** | 69.1%*** | 97.7%*** | 94.7%*** | 46.6%*** |
| Inhibition in prevalence (%) | 22.7%* | 9.3% | 32.0%*** | 35.6%*** | 28.9%** | 32.7%*** | 71.2%*** | 51.0%*** | 5.48% |